Did Kelly Osbourne lose weight on Ozempic? Here's what we know
Quick answer
The video conflates facial volume loss from weight reduction generally with a semaglutide-specific phenomenon, a distinction that matters clinically. GLP-1 receptor agonists like semaglutide and tirzepatide produce weight loss through appetite suppression and delayed gastric emptying, and any significant weight loss can result in facial fat redistribution. Claims about permanent, irreversible side effects attributed to Ozempic use by Sharon Osbourne are based on media interviews rather than clinical documentation, and should not be treated as pharmacological evidence.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @nathanxonline actually say?
The creator claimed Kelly Osbourne has what people call "the gone Ozempic face" and suggested she is likely taking semaglutide or another GLP-1 medication despite her denials. They also stated that Sharon Osbourne "suffers with long lasting negative side effects from taking Ozempic that she cannot reverse." The video frames Kelly's weight loss as suspicious and potentially dangerous, especially given her status as a mother.
To be clear, this video is celebrity speculation dressed up as health commentary. The creator does not have medical records, lab results, or any clinical evidence. They are reading social media reactions and presenting crowd opinion as a kind of informal diagnosis. That is worth naming before going any further.
Does the science back this up?
The term "Ozempic face" is real, but it is not specific to semaglutide. It describes facial volume loss that accompanies rapid weight loss from any cause, and calling it an Ozempic-specific phenomenon is an oversimplification that the evidence does not support.
Rapid weight loss, whether from GLP-1 medications, caloric restriction, bariatric surgery, or illness, causes loss of subcutaneous fat in the face. A 2023 paper by Hwang et al. in Plastic and Reconstructive Surgery noted that facial adipose changes are common with significant weight reduction regardless of method. Semaglutide does not uniquely hollow out faces. The drug causes weight loss, and weight loss causes facial changes. There is no documented mechanism by which semaglutide specifically targets facial fat over other depots.
As for Sharon Osbourne's claimed "irreversible" side effects, that framing is medically imprecise. GLP-1 receptor agonists carry documented side effects, primarily gastrointestinal, and some patients report persistent issues after discontinuation. But "irreversible" is a strong clinical word that requires clinical evidence, not a celebrity interview.
What did they get wrong (or right)?
They got several things wrong. First, diagnosing Kelly Osbourne's weight loss as GLP-1-related based on her appearance is not fact-checking, it is speculation. Osbourne has publicly discussed her weight loss journey for years and has attributed changes to diet and lifestyle at various points. The creator acknowledges her denial and then dismisses it without evidence.
Second, the claim that Sharon's side effects are irreversible is presented as established fact. Sharon Osbourne has spoken about difficult side effects, including excessive weight loss, in interviews. But characterizing those effects as permanently irreversible based on media coverage is not the same as a clinical determination.
What they got right, grudgingly: the concern that visible rapid weight loss in a public figure warrants attention is not unreasonable. GLP-1 medications can cause excessive weight loss in some patients, and clinical guidelines do recommend monitoring for this. The broader point that medication-related weight loss can go too far is grounded in real pharmacology.
What should you actually know?
If you are considering a GLP-1 medication for weight management, the actual clinical picture matters more than celebrity speculation. Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. They are not cosmetic tools, and they are not one-size-fits-all.
Facial volume loss during weight loss is real and documented, but it is a consequence of fat reduction broadly, not a GLP-1-specific side effect. Patients who lose significant weight through any method may notice facial changes. This does not mean the medication is harming them.
Common documented side effects of semaglutide include nausea, vomiting, diarrhea, and constipation, most of which are dose-dependent and tend to improve over time according to the STEP trial series (Wilding et al., 2021, New England Journal of Medicine). Serious side effects are rare but documented, including pancreatitis risk and potential thyroid concerns in rodent models, which is why these medications require clinical supervision.
The takeaway is this: do not use a TikTok video speculating about a celebrity's face to make decisions about your own health. Speak to a licensed clinician.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Did Kelly Osbourne lose weight on Ozempic? Here's what we know, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The video conflates facial volume loss from weight reduction generally with a semaglutide-specific phenomenon, a distinction that matters clinically.
FormBlends verdict
The video conflates facial volume loss from weight reduction generally with a semaglutide-specific phenomenon, a distinction that matters clinically. GLP-1 receptor agonists like semaglutide and tirzepatide produce weight loss through appetite suppression and delayed gastric emptying, and any significant weight loss can result in facial fat redistribution. Claims about permanent, irreversible side effects attributed to Ozempic use by Sharon Osbourne are based on media interviews rather than clinical documentation, and should not be treated as pharmacological evidence.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video conflates facial volume loss from weight reduction generally with a semaglutide-specific phenomenon, a distinction that matters clinically. GLP-1 receptor agonists like semaglutide and tirzepatide produce weight loss through appetite suppression and delayed gastric emptying, and any significant weight loss can result in facial fat redistribution. Claims about permanent, irreversible side effects attributed to Ozempic use by Sharon Osbourne are based on media interviews rather than clinical documentation, and should not be treated as pharmacological evidence.
- Facial volume loss during weight reduction is documented across all weight loss methods, not just GLP-1 medications, per Hwang et al. (2023, Plastic and Reconstructive Surgery).
- Semaglutide's most common side effects are gastrointestinal and tend to be dose-dependent, according to the STEP 1 trial (Wilding et al., 2021, NEJM), not permanent facial changes.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Facial volume loss during weight reduction is documented across all weight loss methods, not just GLP-1 medications, per Hwang et al. (2023, Plastic and Reconstructive Surgery).
- Semaglutide's most common side effects are gastrointestinal and tend to be dose-dependent, according to the STEP 1 trial (Wilding et al., 2021, NEJM), not permanent facial changes.
- No clinical evidence in this video supports the claim that Kelly Osbourne is using any GLP-1 medication. Her denial is dismissed without any counter-evidence.
- The phrase 'irreversible side effects' applied to Sharon Osbourne's Ozempic use comes from media coverage, not medical records or clinical assessment.
- GLP-1 receptor agonists are FDA-approved for chronic weight management and require physician supervision, they are not appropriate for self-directed use based on celebrity outcomes.
- Excessive weight loss is a documented clinical concern with GLP-1 therapy and is addressed through dose titration and clinical monitoring, not by avoiding the medication class entirely.
- Diagnosing someone's medication use from their appearance on social media is not fact-checking. It is speculation, and medical decisions should never be made on that basis.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
NathanX · TikTok creator
343.9K views on this video
@Kelly Osbourne is Unrecognisable 🫨 #kellyosbourne #sharonosbourne #ozzyosbourne #fyp
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by NathanX, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.